Xeljanz Background Information
Rheumatoid Arthritis (approved Nov 2012) , Psoriatic Arthritis (approved Dec 2017), Ulcerative Colitis (approved June 2018)
Xeljanz and Xeljanz XR are immunosuppressive medications that work by inhibiting enzymes (JAK-1 & JAK-3) that signal certain immune responses that may contribute to arthritis and/or colitis. Because Xeljanz impacts the immune system, the risk of serious infection has always been a concern. Health risks related to blood clots in the lungs or pulmonary embolisms were not published by Pfizer.
A MedWatch FDA warning was issued to alert patients and doctors of a public safety study that has shown an increased risk of pulmonary embolism in patients with Rheumatoid Arthritis when taking the 10mg dosage twice daily. The FDA approved the 10mg dosage for Ulcerative Colitis but did not approve the 10mg dosage for RA.
Symptoms & Side Effects
- Sudden shortness of breath or difficulty breathing
- Chest pain or pain in your back
- Coughing up blood
- Excessive sweating
- Clammy or bluish colored skin
- Blood clots
- Heart attack